MedTrace Logo

Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer

NCT06169007 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2023-12-20

No results posted yet for this study

Summary

Checkpoint proteins regulate the immune system; breast cancer cells exploit the up-regulation or down-regulation of these proteins to evade anti-tumour immune responses . It is now well recognized that advanced metastatic BC and early disease are associated with both localized and systemic immune dysfunction .in this study levels of soluble immune checkpoint molecules sTIM3 and sCD40 will be measured and compared with tissue form ,then follow up to patients' prognosis and the relation to markers levels.

Conditions

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Lamiaa Fadel, lecturer · Assiut University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-10-01
Completion
2025-12-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06169007 on ClinicalTrials.gov